



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: February 4, 2011

To: Principal Investigators
Primary Clinical Research Associates

From: Sara Braun / Jack Beranek
Research Protocol Specialists

Re: N0572, A Phase I/II Trial of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma

N078D, Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT)
Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)

Please see the attached letter regarding administration of the drug Torisel which is used in protocols N0572 and N078D. The protocols have been reviewed by the NCCTG Research Base Pharmacy personnel and are in compliance with the information in this letter.

Please review the administration procedures of Torisel at your institution(s) to ensure compliance.

If you have any questions, please feel free to contact me.

Enclosure